We are live on ! Find out more
TLSI icon

TriSalus Life Sciences

53 hedge funds and large institutions have $140M invested in TriSalus Life Sciences in 2021 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 15 increasing their positions, 3 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

634% more capital inflows, than outflows

Capital inflows: $18.9M | Capital outflows: $2.57M

400% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 3

333% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 3

20% more funds holding

Funds holding: 44 → 53 (+9)

5.85% more ownership

Funds ownership: 51.77% → 57.62% (+5.8%)

Holders
53
Holders Change
+9
Holders Change %
+20.45%
% of All Funds
0.92%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
15
Reduced
3
Closed
3
Calls
$63K
Puts
–
Net Calls
+$63K
Net Calls Change
+$63K

TLSI Hedge Fund Activity: Q2 2021 in Review

53 of the 5,769 institutional investors tracked by Wall St. Rank reported a position in TriSalus Life Sciences (TLSI) for Q2 2021, worth a combined $140M — up 12% from $125M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new TLSI positions and 3 closed out — a net gain of 10 holders — while 15 added to existing stakes and 3 trimmed.

The largest buyer was Vestcor Inc, adding an estimated $2.29M. The largest seller was Wellington Management Group, cutting an estimated $1.37M.

  • 53 institutional investors held TriSalus Life Sciences (TLSI) as of Q2 2021, up from 44 in Q1 2021.
  • Funds reported $140M of TriSalus Life Sciences stock for Q2 2021, up 12% quarter-over-quarter.
  • 13 funds opened new TriSalus Life Sciences positions in Q2 2021 and 3 closed out, a net change of +10 holders.
  • The largest TriSalus Life Sciences buyer in Q2 2021 was Vestcor Inc, an estimated $2.29M added.
  • The largest TriSalus Life Sciences seller in Q2 2021 was Wellington Management Group, an estimated $1.37M sold.

Based on aggregated 13F filings for Q2 2021.